CoChat
Sign Up
Cited by 189

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents

Suzman, Daniel L., Pelosof, Lorraine, Rosenberg, Amy, Avigan, Mark I.·2018·Liver International
DOI 10.1111/liv.13746
Open this paper in CoChat — free account

Abstract

Immune checkpoint inhibitors (ICI s) block CTLA‐4, PD‐1 and PD‐L1, or other molecules that control antitumour activities of lymphocytes. These products are associated with a broad array of immune‐related toxicities affecting a variety of organs, including the liver. ICI‐associated immune‐mediated hepatitis (IMH) ranges in severity between mild and life‐threatening and is marked by findings that bear both similarities as well as differences with idiopathic autoimmune hepatitis. Hepatotoxic events are often detected in clinical trials of ICI s that are powered for efficacy. Risk levels for ICI‐induced liver injury may be impacted by the specific checkpoint molecule targeted for treatment, the ICI dose levels, and the presence of a pre‐existing autoimmune diathesis, chronic infection or tumour cells which infiltrate the liver parenchyma. When patients develop liver injury during ICI treatment, a prompt assessment of the cause of injury, in conjunction with the application of measures to optimally manage the adverse event, should be made. Strategies to manage the risk of IMH include the performance of pretreatment liver tests with regular monitoring during and after ICI treatment and patient education. Using Common Terminology Criteria for Adverse Events developed at the National Cancer Institute to measure the severity level of liver injury, recommended actions may include continued ICI treatment with close patient monitoring, ICI treatment suspension or discontinuation and/or administration of corticosteroids or, when necessary, a non‐steroidal immunosuppressive agent. The elucidation of reliable predictors of tumour‐specific ICI treatment responses, as well as an increased susceptibility for clinically serious immune‐related adverse events, would help optimize treatment decisions for individual patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/liv.13746

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 81

  1. 10.1016/j.ccell.2015.03.007 · DOI
  2. 10.1038/nrclinonc.2016.25 · DOI
  3. 10.1016/j.ejca.2017.01.035 · DOI
  4. 10.1111/imr.12531 · DOI
  5. 10.1016/j.clinthera.2015.02.018 · DOI
  6. 10.1189/jlb.5RI0116-013RR · DOI
  7. 10.1126/science.aaa8172 · DOI · Paper page
  8. 10.1155/2016/4683607 · DOI
  9. 10.1016/j.ejca.2017.01.035 · DOI
  10. 10.1200/JCO.2017.74.3062 · DOI
  11. 10.1053/j.seminoncol.2015.05.013 · DOI
  12. 10.1200/JCO.2014.56.2736 · DOI · Paper page
  13. 10.1016/j.ejca.2015.11.016 · DOI · Paper page
  14. 10.1038/nrclinonc.2016.58 · DOI
  15. 10.1111/ajco.12698 · DOI
  16. 10.1007/s11894-017-0540-6 · DOI · Paper page
  17. 10.1158/2326-6066.CIR-16-0237 · DOI
  18. 10.1155/2013/857519 · DOI
  19. Naidoo J, 2015, Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies, Ann Oncol, 26, 2375, 10.1093/annonc/mdv383 · DOI
  20. Grosso JF, 2013, CTLA-4 blockade in tumor models: an overview of preclinical and translational research, Cancer Immun, 13, 5
  21. 10.1073/pnas.87.13.5031 · DOI
  22. 10.4049/jimmunol.177.2.1052 · DOI
  23. 10.1146/annurev.immunol.21.120601.141036 · DOI
  24. 10.1038/nri1349 · DOI
  25. 10.3748/wjg.v17.i28.3322 · DOI
  26. 10.1002/hep.23173 · DOI
  27. 10.1016/j.coi.2010.03.007 · DOI
  28. 10.1158/1078-0432.CCR-13-3271 · DOI · Paper page
  29. 10.1007/s00011-010-0233-1 · DOI
  30. Villadolid J, 2015, Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities, Transl Lung Cancer Res, 4, 560
  31. 10.1002/ijc.30678 · DOI
  32. 10.1038/cti.2014.18 · DOI
  33. 10.1371/journal.pone.0161779 · DOI
  34. 10.1016/j.crad.2017.04.003 · DOI
  35. 2017, Imfinzi (Durvalumab) [Package Insert]
  36. 2017, Opdivo (Nivolumab) [Package Insert]
  37. 2017, Yervoy (Ipilimumab) [Package Insert]
  38. 2017, Bavencio (Avelumab) [Package Insert]
  39. 2017, Tecentriq (Atezolizumab) [Package Insert]
  40. 2017, Keytruda (Pembrolizumab) [Package Insert]
  41. 10.1007/s10620-012-2140-5 · DOI
  42. 10.1038/s41379-018-0013-y · DOI · Paper page
  43. 10.3389/fphar.2017.00049 · DOI
  44. 10.1002/hep.23588 · DOI · Paper page
  45. 10.1007/s10637-013-9939-6 · DOI
  46. 10.1056/NEJMoa1003466 · DOI · Paper page
  47. 10.1053/j.seminoncol.2010.09.007 · DOI
  48. 10.3389/fphar.2017.00730 · DOI
  49. 10.2147/CMAR.S111673 · DOI
  50. 10.1038/cti.2017.47 · DOI
  51. 10.1159/000451016 · DOI
  52. 10.1016/j.jhep.2017.09.007 · DOI
  53. 10.1016/S0140-6736(17)31046-2 · DOI · Paper page
  54. 10.1016/S0140-6736(17)31044-9 · DOI
  55. 10.1016/j.jhep.2013.02.022 · DOI
  56. 10.1200/JCO.2016.72.1167 · DOI
  57. 10.1016/j.jtho.2016.11.446 · DOI
  58. Antonia SJ, 2014, Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results, J Clin Oncol, 32, 8023, 10.1200/jco.2014.32.15_suppl.8023 · DOI
  59. Hammers HJ, 2015, Expanded cohort results from CheckMate 016: a phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC), J Clin Oncol, 33, 10.1200/jco.2015.33.15_suppl.4516 · DOI
  60. 10.1200/JCO.2016.72.1985 · DOI
  61. Segal NH, 2014, A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer, J Clin Oncol, 32, 3007, 10.1200/jco.2014.32.15_suppl.3007 · DOI
  62. 10.1158/1078-0432.CCR-17-1243 · DOI
  63. 10.1158/1538-7445.AM2017-CT117 · DOI
  64. 10.1200/JCO.2017.35.15_suppl.3012 · DOI
  65. 10.1158/0008-5472.CAN-08-4709 · DOI · Paper page
  66. 10.1056/NEJMc1302338 · DOI
  67. 10.1055/s-0034-1375961 · DOI
  68. Amin A, 2014, Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC), J Clin Oncol, 32, 5s, 10.1200/jco.2014.32.15_suppl.5010 · DOI
  69. 10.1016/S0959-8049(16)31440-X · DOI
  70. 10.1016/S1470-2045(18)30081-0 · DOI
  71. 10.1002/hep.27549 · DOI
  72. 10.1093/toxsci/kfx219 · DOI
  73. 10.1021/acs.chemrestox.5b00305 · DOI
  74. 10.1111/j.1529-8019.2009.01233.x · DOI
  75. AviganM.Drug-induced immune injuries: FDA Drug-induced Liver Injury Annual Conference Proceedings.2015;https://www.aasld.org/sites/default/files/documents/DILI/2015/S3P4-Avigan.pdf. Accessed February 15 2018.
  76. 10.1097/COC.0000000000000374 · DOI · Paper page
  77. 10.1093/annonc/mdv623 · DOI · Paper page
  78. 10.1034/j.1600-0528.2002.017401.x · DOI
  79. 10.1016/j.autrev.2010.09.024 · DOI
  80. 10.1056/NEJMp1615879 · DOI
  81. 10.1200/JCO.2017.73.7916 · DOI

Cited by

Sorted by citations

Metadata

Authors
Suzman, D. L., Pelosof, L., Rosenberg, A., & Avigan, M. I.
Venue
Liver International
Publisher
Wiley
Published
2018-04-24
Volume
38
Issue
6
Pages
976-987
ISSN
  • 1478-3223
  • 1478-3231
DOI
10.1111/liv.13746
Cited by
189
References
12
Language
en
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review